Pfizer Warning Letter Shows Challenges Of Upgrading AER Systems
Executive Summary
FDA's warning letter to Pfizer about failures in its post-market adverse event reporting process illustrates the increasing demands that corporate systems are coming under as the agency requests more specific data about patient experiences